Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer

被引:52
作者
Penault-Llorca, Frederique [2 ,3 ]
Abrial, Catherine [1 ,2 ]
Raoelfils, Ines
Cayre, Anne [2 ]
Mouret-Reynier, Marie-Ange [3 ]
Leheurteur, Marianne [3 ]
Durando, Xavier [3 ]
Achard, Jean-Louis [3 ]
Gimbergues, Pierre [3 ]
Chollet, Philippe [3 ,4 ]
机构
[1] Bur Rech Clin, Ctr Jean Perrin, F-63011 Clermont Ferrand, France
[2] INSERM, U484, F-63005 Clermont Ferrand, France
[3] Univ Auvergne, F-63001 Clermont Ferrand 1, France
[4] Ctr Invest Clin, F-63000 Clermont Ferrand, France
关键词
breast cancer; Chevallier's classification; pathologic complete response; Sataloff's classification;
D O I
10.1016/j.humpath.2007.11.019
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Pathologic complete response (pCR) is linked to a better outcome, but its definition varies among working groups. We performed this study to validate different expressions of pCR as well as to determine the role of in situ and isolated tumor cell residues. A pathologic review was conducted on 710 operable patients with breast cancer to assess the residual disease in breast and in nodes according to the Chevallier (Ch) and Sataloff's (Sa) classifications. The pCR rate was 14.3% according to the Chevallier and 25.8% according to the Sataloffs classification. Overall survival and disease-free survival have been compared according to the pathologic response. There were significant differences between the pCR Ch(1+2) or Sa(A) and the non-pCR group. No significant difference was found between classes Ch(1) versus Ch(2) and between class Sa(A) without isolated cells versus class Sa(A) with isolated cells. Conversely, tumors histologically modified by chemotherapy were associated with a better prognosis than unmodified tumors. Finally, evidence of pCR in nodes was associated with a better prognosis. pCR should be defined as an absence of node invasion, and in the breast, either absence of tumor or tumor residue less than 5% of the tumor. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1221 / 1228
页数:8
相关论文
共 22 条
[1]   Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers [J].
Abrial, C ;
Mouret-Reynier, MA ;
Amat, S ;
Sillet-Bach, I ;
Bougnoux, P ;
Delva, R ;
Cure, H ;
Dauplat, J ;
Penault-Llorca, F ;
Chollet, P .
MEDICAL ONCOLOGY, 2005, 22 (03) :233-240
[2]   Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer [J].
Abrial, C ;
Van Praagh, I ;
Delva, R ;
Leduc, B ;
Fleury, J ;
Gamelin, E ;
Sillet-Bach, I ;
Penault-Llorca, F ;
Amat, S ;
Chollet, P .
ONCOLOGIST, 2005, 10 (04) :242-249
[3]   High prognostic significance of residual disease after neoadjuvant chemotherapy:: a retrospective study in 710 patients with operable breast cancer [J].
Amat, S ;
Abrial, C ;
Penault-Llorca, F ;
Delva, R ;
Bougnoux, P ;
Leduc, B ;
Mouret-Reynier, MA ;
Mery-Mignard, D ;
Bleuse, JP ;
Dauplat, J ;
Curé, H ;
Chollet, P .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (03) :255-263
[4]   Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate [J].
Amat, S ;
Bougnoux, P ;
Penault-Llorca, F ;
Fétissof, F ;
Curé, H ;
Kwiatkowski, F ;
Achard, JL ;
Body, G ;
Dauplat, J ;
Chollet, P .
BRITISH JOURNAL OF CANCER, 2003, 88 (09) :1339-1345
[5]   Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer [J].
Amat, Sophie ;
Mouret-Reynier, Marie-Ange ;
Penault-Llorca, Frederique ;
Leheurteur, Marianne ;
Delva, Remi ;
Coudert, Bruno ;
Leduc, Bernard ;
Dauplat, Jacques ;
Cure, Herve ;
Chollet, Philippe .
CLINICAL BREAST CANCER, 2006, 7 (03) :262-269
[6]   NEOADJUVANT CHEMOTHERAPY IN 126 OPERABLE BREAST CANCERS [J].
BELEMBAOGO, E ;
FEILLEL, V ;
CHOLLET, P ;
CURE, H ;
VERRELLE, P ;
KWIATKOWSKI, F ;
ACHARD, JL ;
LEBOUEDEC, G ;
CHASSAGNE, J ;
BIGNON, YJ ;
DELATOUR, M ;
LAFAYE, C ;
DAUPLAT, J .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :896-900
[7]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[8]   Neoadjuvant chemotherapy for breast carcinoma - Multidisciplinary considerations of benefits and risks [J].
Buchholz, TA ;
Hunt, KK ;
Whitman, GJ ;
Sahin, AA ;
Hortobagyi, GN .
CANCER, 2003, 98 (06) :1150-1160
[9]   American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome [J].
Carey, LA ;
Metzger, R ;
Dees, EC ;
Collichio, F ;
Sartor, CI ;
Ollila, DW ;
Klauber-DeMore, N ;
Halle, J ;
Sawyer, L ;
Moore, DT ;
Graham, ML .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (15) :1137-1142
[10]   INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE [J].
CHEVALLIER, B ;
ROCHE, H ;
OLIVIER, JP ;
CHOLLET, P ;
HURTELOUP, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03) :223-228